Health Care • Medical/Dental Instruments
$9.61 ▲ +0.17
(+1.80%)
MKT CAP: $1.92B • VOL: 3.55M
52W L $8 52W H $15
XRAY // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $3.68B | $3.79B | $3.96B |
| YoY Revenue Growth % | -3.0% | -4.3% | — |
| Gross Profit | $1.84B | $1.96B | — |
| Gross Margin % | 50.0% | 51.6% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$422.0M | -$879.0M | -$85.0M |
| Operating Margin % | -11.5% | -23.2% | -2.1% |
| Net Income (GAAP) | -$598.0M | -$910.0M | -$132.0M |
| EBITDA (Normalized) | — | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $235.0M | $461.0M | $377.0M |
| Capital Expenditures (CapEx) | — | — | — |
| Free Cash Flow (FCF) | $235.0M | $461.0M | $377.0M |
| FCF Margin % | 6.4% | 12.2% | 9.5% |
| Return on Invested Capital (ROIC %) | -11.0% | -21.3% | — |
| Cash & Short-Term Equivalents | $326.0M | $272.0M | — |
| Total Debt (Short + Long Term) | $2.02B | $1.59B | — |
| Total Stockholders' Equity | $1.34B | $1.94B | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR XRAY.